Key facts
- Exothera’s last known valuation is $108.4M (Jan 2025).
- It has raised $69.5M; the latest was Later Stage VC ($33.2M) in Jan 2025.
- Notable investors include SambrInvest.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Exothera
- ·The full record, as it builds
Funding rounds
No funding rounds for Exothera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Exothera
Provider of contract manufacturing and development services intended to design and deliver affordable viral vector-based vaccines and cell and gene therapies. The company capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide custom-made process optimization and GMP clinical and commercial production of viral vectors, enabling customers with services such as process analysis, design, and development for cost-effective and agile viral vector manufacturing.
- Sector
- Healthcare
- HQ
- Nivelles, Belgium
- Founded
- 2020
- Employees
- 159
- Website
- exothera.world/
- Ownership
- Privately Held (backing)
Exothera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Exothera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Exothera in its N-PORT filings yet. We sweep new filings monthly.